Abstracts tagged "interstitial lung disease"

Abstract Number: 1537 • ACR Convergence 2023
Long-term Observational Study of Interstitial Lung Disease in ANCA-associated Vasculitis
aglaia chalkia¹, Dr Rachel Jones², Pasupathy Sivasothy³ and David Jayne⁴, ¹Department of Medicine, University of Cambridge, Cambridge, United Kingdom, ²Vasculitis and Lupus Clinic, Addenbrooke's Hospital, Cambridge, United Kingdom, ³Vasculitis and Lupus Clinic, Addenbrooke's Hospital, Cambridge, United Kingdom, ⁴University of Cambridge, Cambridge, United Kingdom
Background/Purpose: There is limited data on the epidemiology and long-term outcome of patients with Interstitial Lung Disease (ILD) in ANCA-associated Vasculitis (AAV) with conflicting results…
Abstract Number: 1949 • ACR Convergence 2023
Relapse of Rapidly Progressive Interstitial Lung Disease in Patients with Anti-Melanoma Differentiation-Associated Gene 5 Autoantibody-Positive Dermatomyositis
Noriko Sasaki, Toshiki Ohisa, Akira Ishii, Mai Sugiyama, Yuichiro Ota, Chiho Yamada and Shinji Sato, Tokai university School of Medicine, Isehara, Japan
Background/Purpose: Autoantibodies to Melanoma Differentiation-Associated Gene 5 (MDA5) are found specifically in patients with dermatomyositis (DM). Their presence is closely associated with rapidly progressive interstitial…
Abstract Number: 2479 • ACR Convergence 2023
Tolerability and Effectiveness of Antifibrotics in Rheumatoid Arthritis-associated Interstitial Lung Disease
Pierre-Antoine Juge¹, Keigo Hayashi², Gregory McDermott², Kathleen Vanni², Emily Kowalski², Grace Qian², Katarina Bade³, Alene Saavedra², Philippe Dieudé⁴, Paul Dellaripa³, Tracy J. Doyle² and Jeffrey Sparks⁵, ¹Division of Rheumatology, Inflammation, and Immunity Brigham & Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, INSERM UMR1152, University de Paris Cité, Department of Rheumatology, Paris, France, ⁵Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Nintedanib and pirfenidone are antifibrotic drugs indicated for the treatment of idiopathic pulmonary fibrosis (IPF) and other forms of progressive pulmonary fibrosis. Antifibrotics have…
Abstract Number: 0256 • ACR Convergence 2023
Nintedanib in Combination with Immunosuppressive Agents Improves Forced Vital Capacity in Connective Tissue Disease-associated PF-ILD: A Single-center Study
Yusuke Ushio¹, Risa Wakiya², Tomohiro Kameda², Shusaku Nakashima², Hiromi Shimada², Taichi Miyagi³, Koichi Sugihara⁴, Rina Mino⁵, Mao Mizusaki², Kanako Chujo⁶, Ryoko Kagawa⁷, Hayamasa Yamaguchi⁷ and Hiroaki Dobashi², ¹Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki, Kita District, Kagawa, Japan, ²Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan, ³Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Kidagun, Japan, ⁴Kagawa University, Miki-cho, Kita-gun, Japan, ⁵Kagawa University, Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa, Japan, ⁶Kagawa University, Miki, Kita District, Kagawa, Japan, ⁷Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Japan
Background/Purpose: Japanese patients with connective tissue disease (CTD) are more likely to have interstitial lung disease (CTD-ILD) than those in Western countries and many CTD-ILDs…
Abstract Number: 0624 • ACR Convergence 2023
Outcomes in Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) Based on Serological Profiles: Focus on Anti-Centromere Antibody (ACA) and Anti-RNA Polymerase III (ARA) Antibodies
Elizabeth Volkmann¹, Shervin Assassi², Christopher Denton³, Rozeta Simonovska⁴, Steven Sambevski⁵ and Elana Bernstein⁶, ¹University of California Los Angeles, Los Angeles, CA, ²University of Texas McGovern Medical School at Houston, Houston, TX, ³University College London, London, United Kingdom, ⁴Mainanalytics GmbH, Sulzbach (Taunus), Sulzbach, Germany, ⁵Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, ⁶Division of Rheumatology, Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY
Background/Purpose: Autoantibody profiles are associated with organ involvement and outcomes in patients with SSc. Anti-topoisomerase I antibody (ATA) positivity has been associated with a greater…
Abstract Number: 0773 • ACR Convergence 2023
Sputum Lautropia Abundance Is Decreased in Rheumatoid Arthritis-Associated Pulmonary Fibrosis and Correlates with Lung Disease Severity
Timothy Wilson¹, Brendan Allen², jonathan harris³, Stephen Humphries⁴, kristine Kuhn², kevin Deane³, joyce Lee⁵, joshua Solomon⁴ and Kristen Demoruelle³, ¹Thomas Jefferson University, Philadelphia, PA, ²University of Colorado School of Medicine, Aurora, CO, ³University of Colorado Anschutz Medical Campus, Aurora, CO, ⁴National Jewish Health, Denver, CO, ⁵University of Colorado Anschutz Campus, Denver, CO
Background/Purpose: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) develops in 5-10% of RA patients and more often manifests as the fibrotic subtype of ILD known as…
Abstract Number: 1165 • ACR Convergence 2023
Long-term Changes in Lung Function in Melanoma Differentiation-associated Protein 5 (MDA5) Antibody Positive Dermatomyositis Patients: Experience of a Single Center Longitudinal Cohort in North America
Jenice Cheah¹, Sangmee Bae², Tiffany De Leon², Yuna Lee¹ and Christina Charles-Schoeman³, ¹University of California Los Angeles, Los Angeles, CA, ²UCLA Rheumatology, Los Angeles, CA, ³UCLA Medical Center, Santa Monica, CA
Background/Purpose: Interstitial lung disease (ILD) associated with antibodies to melanoma differentiation-associated protein 5 (MDA5 ab) in patients with dermatomyositis (DM) has been associated with a…
Abstract Number: 1582 • ACR Convergence 2023
Non-TNFi b/tsDMARDs vs. TNFi in Rheumatoid Arthritis-Interstitial Lung Disease: An Active-Comparator, New-User, Propensity Score Matched Study Using National Veterans Affairs Data
Bryant England¹, Joshua Baker², Michael George², Tate Johnson¹, Yangyuna Yang¹, Punyasha Roul¹, Harlan Sayles¹, Fang Yu¹, Jorge Rojas Jr³, Brian Sauer⁴, Grant Cannon⁵, Jeffrey R Curtis⁶ and Ted R Mikuls⁷, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Pennsylvania, Philadelphia, PA, ³Puget Sound VA and University of Utah, Seattle, WA, ⁴Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁵University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁶Division of Clinical Immunology and Rheumatology, University of Alabama, Birmingham, AL, ⁷Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: There is a paucity of data to guide biologic and JAKi DMARD selection in rheumatoid arthritis-interstitial lung disease (RA-ILD), with some reports of higher…
Abstract Number: 1952 • ACR Convergence 2023
Anti-MDA5 Associated Dermatomyositis: Clinical Features and Outcomes in a Predominantly African-American Case Series
David Wang¹, Arezou Khosroshahi² and Prateek Gandiga², ¹Emory University School of Medicine, Atlanta, GA, ²Emory University, Atlanta, GA
Background/Purpose: Individuals with autoantibodies against melanoma differentiation-associated protein 5 (MDA-5) are reported to have a significant risk of developing rapidly progressive and fatal interstitial lung…
Abstract Number: 2518 • ACR Convergence 2023
Could the Adenosine Pathway Identify Cases with a Progressive Fibrosing Phenotype Between Patients with Autoimmune Interstitial Lung Disease? An Initial Approach
Olga Sanchez Pernaute¹, Cristina Vadillo-Font², Hilda Godoy³, Laura Cebrian⁴, Gema Bonilla⁵, Rosario Garcia-Vicuna⁶, Irene Llorente Cubas⁶, Fredeswinda Romero¹, Rosalía Laporta³, Belen Lopez-Muñiz⁴, M Asunción Nieto⁷, Luis Gomez-Carrera⁵, Claudia Valenzuela⁸, M Jesus Rodriguez-Nieto⁹ and lydia Abasolo¹⁰, ¹IIS-HU Fundación Jiménez Díaz, Madrid, Spain, ²Hospital Clinico San Carlos, Madrid, Spain, ³Hospital Universitario Puerta de Hierro, Madrid, Spain, ⁴Hospital Universitario Infanta Leonor, Madrid, Spain, ⁵Hospital Univ. La Paz, Madrid, Spain, ⁶Hospital Universitario de la Princesa, Madrid, Spain, ⁷Hospital Clínico S. Carlos, Madrid, Spain, ⁸Hospital Universitario La Princesa, Madrid, Spain, ⁹Pulmonology department, Hospital Fundación Jimenez Díaz, Madrid, Spain, ¹⁰Hospital Clínico San Carlos, Madrid, Spain
Background/Purpose: Interstitial lung diseases with an autoimmune background (AIP) are a heterogeneous group of processes. There is an unmet need to identify those cases with…
Abstract Number: 0266 • ACR Convergence 2023
E-selectin, ICAM-1 and ET-1 Biomarkers Address the Concern of the Challenging Diagnosis of Interstitial Lung Disease in Patients with Autoimmune Diseases
Verónica Pulito-Cueto¹, Sara Remuzgo-Martinez², Fernanda Genre Romero², Belén Atienza-Mateo³, Victor Mora-Cuesta⁴, David Iturbe-Fernández⁴, Leticia Lera-Gómez⁵, María Sebastián-Mora¹, Virginia Portilla¹, Alfonso Corrales¹, Ricardo Blanco¹, Jose Cifrian⁶, Miguel A Gonzalez-Gay⁷ and Raquel López-Mejías¹, ¹Rheumatology Department, Immunopathology Group, Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, Spain, ²IDIVAL, Santander, Spain, ³Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁴Immunopathology Group, Marqués de Valdecilla University Hospital-IDIVAL; Department of Pneumology, Marqués de Valdecilla University Hospital, Santander, Spain, ⁵Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁶Immunopathology Group, Marqués de Valdecilla University Hospital-IDIVAL; Department of Pneumology, Marqués de Valdecilla University Hospital; School of Medicine, Cantabria University, Santander, Spain, ⁷IDIVAL and School of Medicine, UC, Santander; Department of Rheumatology, IIS-Fundación Jiménez Díaz, Madrid, Santander, Spain
Background/Purpose: Interstitial lung disease (ILD) constitutes one of the most critical comorbidities in autoimmune diseases (AD), particularly in rheumatoid arthritis (RA) and systemic sclerosis (SSc)…
Abstract Number: 0627 • ACR Convergence 2023
Clinical Significance of Anti-Ro/SSA Antibodies in Patients with Systemic Sclerosis: A Study from the EUSTAR Database
Blaz Burja¹, Marouane Boubaya², Patricia Carreira³, Christina Bergmann⁴, Lidia P Ananieva⁵, Gabriela Riemekasten⁶, Okada Masado⁷, Jeska de Vries-Bouwstra⁸, Edoardo Rosato⁹, Marie-Elise Truchetet¹⁰, Nicoletta Del Papa¹¹, Antonella Marcoccia¹², FABIOLA ATZENI¹³, Tim Schmeiser¹⁴, Madelon Vonk¹⁵, Francesco Del Galdo¹⁶, Oliver Distler¹⁷ and Muriel Elhai¹⁸, ¹Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ²Department of Clinical Research, CHU Avicenne, APHP, Bobigny, France, ³Hospital Universitario 12 de Octubre, Madrid, Spain, ⁴Department Internal Medicine, University Hospital Erlangen, Germany, Erlangen, Germany, ⁵V.A. Nasonova Research Institute Of Rheumatology Russian Federation, Moscow, Russia, ⁶University Clinic Schleswit-Holstein (UKSH), Lübeck, Germany, ⁷St.Luke's International Hospital Immuno-Rheumatology Center, Tokyo, Japan, ⁸Leiden University Medical Center, Leiden, Netherlands, ⁹Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy, ¹⁰Bordeaux University Hospital, Bordeaux, France, ¹¹Scleroderma Clinic, UOC Reumatologia Clinica, ASST G. Pini-CTO, Milano, Italy, ¹²Centro Di Riferimento Interdisciplinare Per La Sclerosi Sistemica, Rome, Italy, ¹³Rheumatology Unit, Univerity of Messina, Messina, Italy, ¹⁴Krankenhaus St. Josef, Wuppertal-Elberfeld, Germany, ¹⁵Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ¹⁶University of Leeds - Leeds Institute of Rheumatic and Muskuloskeletal Medicine, Leeds, United Kingdom, ¹⁷Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ¹⁸Department of Rheumatology, University Hospital Zurich, University of Zurich, Schlieren, Switzerland
Background/Purpose: Despite the progress in understanding the patient heterogeneity in systemic sclerosis (SSc) based on SSc-specific antibodies, better risk stratification is needed. SSc non-specific antibodies…
Abstract Number: 0774 • ACR Convergence 2023
Deciphering Rheumatoid Arthritis-associated Interstitial Lung Disease Phenotypes Using Unsupervised Hierarchical Clustering Analysis: Results from a Large Collaborative International Study
Pierre-Antoine Juge¹, Benjamin Granger², Lina El Houari³, Gregory McDermott⁴, Tracy J. Doyle⁴, Clive Kelly⁵, Gouri M Koduri⁶, Robert Vassallo⁷, Amarilys Alarcon Calderon⁷, Umut Kalyoncu⁸, Antonio Gonzalez⁹, Natalia Mena Vazquez¹⁰, Marta Rojas¹¹, Raquel Dos-Santos¹², Miriam Retuerto-Guerrero¹³, Cristina Vadillo-Font¹⁴, PALOMA VELA¹⁵, Antonio Fernandez-Nebro¹⁶, Alejandro Escudero-Contreras¹⁷, Eva Perez-Pampin¹⁸, Charlotte Hyldgaard¹⁹, Antoine Froidure²⁰, Patrick Durez²¹, Jorge Rojas Serrano²², Coline van Moorsel²³, Jan C Grutters²³, Leticia Kawano-Dourado²⁴, Charlotte Lucas²⁵, Stephane Jouneau²⁶, Raimon Sanmarti²⁷, Raul Castellanos Moreira²⁸, Katarina Antoniou²⁹, Maria Molina molina³⁰, joshua Solomon³¹, Sophia raia³¹, Miguel A Gonzalez-Gay³², Belén Atienza-Mateo³³, Sofia Flouda³⁴, Effrosyni Manali³⁴, Boumpas Dimitrios³⁵, Spyros Papiris³⁴, THEOFANIS KARAGEORGAS³⁶, Marco Sebastiani³⁷, Andreina Manfredi³⁸, Ana Catarina Duarte³⁹, Santos Castañeda⁴⁰, Lorenzo Cavagna⁴¹, Bruno Crestani⁴², Jeffrey Sparks⁴³ and Philippe Dieudé⁴⁴, ¹Division of Rheumatology, Inflammation, and Immunity Brigham & Women's Hospital, Boston, MA, ²Sorbonne Université, INSERM, and Pitié Salpêtrière Hospital, Paris, France, ³Institut Pierre Louis d’Epidémiologie et de Santé Publique, Paris, France, ⁴Brigham and Women's Hospital, Boston, MA, ⁵James Cook University Hospital, Middlesbrough, United Kingdom, ⁶Southend University Hospitals NHS Trust, Essex, United Kingdom, ⁷Mayo Clinic, Rochester, MN, ⁸Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ⁹Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, ¹⁰IBIMA, Málaga, Spain, ¹¹Hospital Universitario Reina Sofía, Cordoba, Spain, ¹²Clinical University Hospital in Santiago de Compostela, Santiago de Compostela, Spain, ¹³Rheumatology, Hospital Universitario de León, León, Spain, ¹⁴Hospital Clínico San Carlos – Instituto Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain, ¹⁵Rheumatology, Hospital General Universitario Alicante, Alicante, Spain, ¹⁶Hospital Regional Universitario de Málaga, Malaga, Spain, ¹⁷Rheumatology Department, Reina Sofia University Hospital, Cordoba/Maimonides Biomedical Research Institute of Cordoba (IMIBIC)/University of Cordoba, Córdoba, Spain, ¹⁸Rheumatology Department Complejo Hospitalario Universitario Santiago, Santiago de compostela, Spain, ¹⁹Silkeborg Regional Hospital, Silkeborg, Denmark, ²⁰Université Catholique de Louvain, Louvain, Belgium, ²¹UCLouvain, Brussels, Belgium, ²²Hospital Angeles Villahermosa, Ciudad de Mexico, Mexico, ²³St. Antonius Hospital, Nieuwegein, Netherlands, ²⁴Hospital do Coração (HCor), São Paulo, Brazil, ²⁵CHU, Rennes, France, ²⁶Amicus, Boca Raton, FL, ²⁷Hospital Clinic, Rheumatology, Barcelona, Spain, ²⁸Hospital Clínic de Barcelona, Madrid, Spain, ²⁹University of Crete, Heraklion, Greece, ³⁰IDIBELL Bellvitge Biomedical Research Institute, Barcelona, Spain, ³¹National Jewish Health, Denver, CO, ³²IDIVAL and School of Medicine, UC, Santander; Department of Rheumatology, IIS-Fundación Jiménez Díaz, Madrid, Santander, Spain, ³³Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³⁴Unit of Attikon University Hospital, Athens, Greece, ³⁵National and Kapodistrian University of Athens, Athens, Greece, ³⁶n/a, Athina, Greece, ³⁷Azienda Policlinico di Modena, Modena, Italy, ³⁸University of Modena, Modena, Italy, ³⁹Hospital Garcia de Orta, Almada, Portugal, ⁴⁰Hospital Universitario de la Princesa, Madrid, Spain, ⁴¹Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, ⁴²Hopital Bichat, Paris University, Paris, France, ⁴³Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ⁴⁴Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, INSERM UMR1152, University de Paris Cité, Department of Rheumatology, Paris, France
Background/Purpose: RA-associated interstitial lung disease (ILD) is not a single entity as illustrated by different HRCT patterns, different risk factors and prognoses suggesting heterogenous phenotypes.…
Abstract Number: 1167 • ACR Convergence 2023
Transcriptome Analysis of Peripheral Blood Reveals Superiority of the Triple Combination of Baricitinib, Rituximab, and Tacrolimus Therapy (BRT-Tx.) for anti-MDA5 Antibody-positive Dermatomyositis (MDA5-DM)
Yoshinobu Koyama¹, Yoshiharu Sato², Yu Nakai³ and Moe Tokunaga(Sakamoto)³, ¹Japanese Red Cross Okayama Hospital, Okayama, Japan, ²DNA Chip Research Inc, Tokyo, Japan, ³Rheumatology, Center for Autoimmune diseases, Japanese Red Cross Okayama Hospital, Okayama, Japan
Background/Purpose: MDA5-DM is characterized by high mortality due to rapid progressive ILD. We reported that in MDA-5DM, (1) RIG-1-like receptor signaling is enhanced, (2) antiviral…
Abstract Number: 1660 • ACR Convergence 2023
Still’s Disease Patients with High Interferon-stimulated Gene Expression Have Enrichment of Rare, de Novo and Recessive Protein Altering Variants in Innate Immune Pathways
Mariana Correia Marques¹, Zuoming Deng², Navid Chowdhury², Elizabeth Schmitz³, Alana Platukus⁴, Stephen Brooks⁵, Carol Lake², Ly-Lan Bergeron², Michelle Millwood² and Michael Ombrello⁶, ¹National Institute of Arthritis & Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), St. Louis, MO, ⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Philadelphia, PA, ⁵Biodata Mining and Discovery Section, National Institute of Arthritis and Musculoskeletal and Skins Diseases, National Institutes of Health, Bethesda, MD, ⁶National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), North Bethesda, MD
Background/Purpose: Still’s disease (systemic juvenile idiopathic arthritis in children, adult-onset Still’s disease in adults) is an enigmatic inflammatory condition that affects people of all ages.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].